All-Hydrocarbon Stapling and Amino Acid Substitution-Modified Antimicrobial Peptide Feleucin-K3 Analogs Enhanced the Stability and Optimized the Therapeutic Index against Multidrug-Resistant Bacteria.
Feleucin-K3 just got an upgrade. Researchers from Lanzhou University have taken this classic antimicrobial peptide and made it tougher, safer, and far more effective against multidrug-resistant bacteria. They did it by combining two hot techniques in peptide science: all-hydrocarbon stapling and amino acid substitution.
J Med Chem
by Gao B, Jia Y, Yan T et al.
“All-Hydrocarbon Stapling and Amino Acid Substitution-Modified Antimicrobial Peptide Feleucin-K3 Analogs Enhanced the Stability and Optimized the Therapeutic Index against Multidrug-Resistant Bacteria. Gao B(1)(2), Jia Y(1), Yan T(1), Jiao R(1), Cai X(1), Yang W(1), Dai W(1), Ma B(1), Bai H(1)(3), Bai X(1)(3), Ran J(1), Miao X(1), Sun W(1), Yang W(1), Bao G(1), Xie J(1). Author information: (1)Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Lanzhou University, Lanzhou 730000, China. (2)Department of Pharmacy, Gansu Provincial Hospital, Lanzhou 730000, China. (3)Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou 730000, China. Our previous research found that the poor stability of the antimicrobial peptide Feleucin-K3 (FK3) had limited its transition into clinical application. Herein, we developed a series of FK3 derivatives stapled by all-hydrocarbon and thioether to enhance the stability and then implemented an amino acid substitution strategy to reduce the hemolytic toxicity. Consequently, after replacing the first phenylalanine of FK3 with alanine and conducting (i, i + 4) all-hydrocarbon stapling with (S)-2-(4-pentenyl) alanine at the 5,9-position, analog S1-1A displayed the highest therapeutic index, high stability, and potent antimicrobial effects against multidrug-resistant (MDR) bacteria as well as antibiofilm properties. A striking finding was that S1-1A exhibited 8-fold greater antimicrobial activity against resistant strains of Staphylococcus aureus than vancomycin. The efficacy of S1-1A in vivo was as effective as vancomycin in the skin wound infection model. Overall, stapled peptide S1-1A showed promising potential for being developed into a novel drug for combating MDR bacterial infections.”
The problem: Feleucin-K3 is potent, but doesn’t last long in the body and can be harsh on healthy cells. That’s a dealbreaker for clinical applications. The team systematically modified the peptide. First, they used hydrocarbon staples (think: molecular “brace” to lock the structure in place) to boost stability. Then, they swapped out certain amino acids to reduce toxicity—especially hemolytic activity, which is a fancy way of saying “doesn’t wreck red blood cells.”
Key takeaway: One analog, called S1-1A, crushed it in the lab. It was at least eight times more powerful than vancomycin (an antibiotic of last resort) against resistant Staph aureus. It also performed just as well as vancomycin in a mouse skin infection model. This analog didn’t just kill planktonic bacteria; it also broke down biofilms, which are notoriously hard to treat.
Why does this matter for peptide researchers?
Shows that peptide stability and specificity can be optimized with modern design tricks
Highlights the value of all-hydrocarbon stapling for toughening up antimicrobial candidates
S1-1A could serve as a template for developing other next-gen research peptides
Anyone interested in pushing peptide science forward should watch this space. The work is a strong case study in how rational design can turn promising peptides into real contenders. For more breakthroughs and analog details, check the peptide research index. This is the kind of progress that keeps the field moving.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.